Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.33 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18651739 | 0.89 | SMYD3 (0.33) | SMYD3 | |
| SCHEMBL4197975 | 0.87 | SMYD3 (0.46) | ALDH1A1MAPTHSD17B10TP53MAPK1 | |
| SCHEMBL13854234 | 0.86 | HSD17B10 (0.34) | MAPTHSD17B10SMYD3TDP1 | |
| SCHEMBL13854237 | 0.86 | THRB (0.35) | SMYD3 | |
| SCHEMBL13854232 | 0.85 | SMYD3 (0.32) | SMYD3 | |
| SCHEMBL13854246 | 0.83 | ALDH1A1 (0.37) | ALDH1A1MAPTHSD17B10TP53MAPK1 | |
| SCHEMBL13854223 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTHSD17B10TP53MAPK1 | |
| SCHEMBL13854248 | 0.78 | ALDH1A1 (0.34) | ALDH1A1MAPTHSD17B10TP53MAPK1 | |
| SCHEMBL4199097 | 0.74 | SMYD3 (0.45) | SMYD3 | |
| SCHEMBL4202518 | 0.73 | SMYD3 (0.44) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| US-20090130165-A1 | MIF Inhibitors | CORTICAL PTY LTD | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130165-A1 | MIF Inhibitors | MIF, MMP12, IL4 | ALDH1A1 780/4885MAPT 4279/4885HSD17B10 2179/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | ALDH1A1 435/4885MAPT 4512/4885HSD17B10 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.